超声探测包膜侵犯对微波消融治疗甲状腺微小乳头状癌影响的多中心前瞻性队列研究
多中心前瞻性队列研究纳入461例≤1cm无淋巴结转移的PTMC患者,比较超声探测包膜侵犯组(83例)与无侵犯组(378例)接受微波消融的可行性与安全性。两组技术成功率、并发症、疾病进展及肿瘤缩小均无显著差异,提示伴包膜侵犯的PTMC微波消融短期疗效相当。
要点
- 超声评估包膜侵犯是PTMC微波消融术前分组的可行依据。
- 伴包膜侵犯的PTMC微波消融技术成功率达99%,短期疗效与无侵犯者相当。
- 两组并发症、疾病进展及肿瘤缩小率均无统计学差异。
核心结论
- 微波消融治疗超声探测包膜侵犯的甲状腺微小乳头状癌是可行的,其短期疗效与无包膜侵犯者相当。
研究设计与样本
- 前瞻性多中心队列研究,纳入12家医院461例最大径≤1cm、无超声或CT检出淋巴结转移的PTMC患者,按术前超声有无包膜侵犯分组。
- 共83例伴包膜侵犯、378例无包膜侵犯,平均年龄43岁±11,女性337例,随访至2022年7月1日。
- 主要终点为技术成功与疾病进展,次要终点包括治疗参数、并发症及随访中肿瘤缩小,并进行多因素回归分析。
关键影像表现/征象
- 术前超声将所有肿瘤分为伴包膜侵犯与不伴包膜侵犯两组,作为分组依据。
诊断标准与关键数值
- 伴与不伴包膜侵犯组技术成功率分别为99%(82/83)与100%(378/378),P=.18。
- 伴包膜侵犯组并发症1%(1/82),无侵犯组3%(11/378),P=.38。
- 疾病进展率分别为2%(1/82)与1%(4/378),P=.82;肿瘤平均缩小分别为97%±8与96%±13,P=.58。
临床应用与阅片要点
- 术前超声应仔细评估PTMC是否侵犯包膜,为微波消融适应证选择和预后沟通提供依据。
- 对超声探测包膜侵犯的PTMC,微波消融可作为可行治疗选项,但仍需长期随访验证。
局限性
- 随访时间较短(平均约20个月),仅评估短期疗效。
- 单例伴包膜侵犯者因技术失败中止消融。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Microwave ablation (MWA) has achieved favorable results in the treatment of papillary thyroid microcarcinoma (PTMC) confined in glandular parenchyma. However, studies on the outcome of MWA for PTMC with US-detected capsular invasion remain unclarified in the literature. Purpose To compare the feasibility, effectiveness, and safety of MWA in the treatment of PTMC with and without US-detected capsular invasion. Materials and Methods Participants from 12 hospitals with a PTMC maximal diameter of 1 cm or less without US- or CT-detected lymph node metastasis (LNM) who planned to undergo MWA were enrolled in this prospective study between December 2019 and April 2021. All tumors were evaluated with preoperative US and were divided into those with and those without capsular invasion. The participants were observed until July 1, 2022. The primary end points, including technical success and disease progression, and the secondary end points, including treatment parameters, complications, and tumor shrinkage during follow-up, were compared between the two groups, and multivariable regression was performed. Results After exclusion, 461 participants (mean age, 43 years ± 11 [SD]; 337 women) were included: 83 with and 378 without capsular invasion. After one participant with capsular invasion aborted MWA because of technical failure, 82 participants with and 378 participants without capsular invasion (mean tumor volume, 0.1 mL ± 0.1 vs 0.1 mL ± 0.1; P = .07) were analyzed with a mean follow-up period of 20 months ± 4 (range, 12-25 months) and 21 months ± 4 (range, 11-26 months), respectively. In those with and those without capsular invasion, comparable technical success rates were achieved (99% [82 of 83] vs 100% [378 of 378], P = .18), with one and 11 complications, respectively (1% [one of 82] vs 3% [11 of 378], P = .38). There was no evidence of differences in disease progression (2% [one of 82] vs 1% [four of 378]; P = .82) or tumor shrinkage (mean, 97% ± 8 [SD] vs 96% ± 13; P = .58). Conclusion Microwave ablation was feasible in the treatment of papillary thyroid microcarcinoma with US-detected capsular invasion and showed comparable short-term efficacy with or without the presence of capsular invasion. © RSNA, 2023 Clinical trial registration no. NCT04197960 Supplemental material is available for this article.
引用
- Zheng, Dou, Han, et al. Microwave Ablation for Papillary Thyroid Microcarcinoma with and without US-detected Capsule Invasion: A Multicenter Prospective Cohort Study. Radiology. 2023. PMID: 36880949. doi:10.1148/radiol.220661
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。